Full Text
Full Text PDF
Abstract
Abstract The meta-analyses of observational studies (OBS) showed the risk of any fracture and hip fracture slightly increased with proton pump inhibitor (PPI) treatment depending on the dose and regardless of time. This was not observed with histamine-2 receptor antagonists (H2RA). The risk of bacterial overgrowth and spontaneous bacterial peritonitis were increased with PPI therapy, but not with H2RA. In meta-analyses of OBS, a slight increase was observed in the risk of community-acquired pneumonia (CAP) in the early stages (<1 month) of PPI use and particularly at high doses. In a five-year LOTUS study, no difference was found in vitamin B12, folic acid, vitamin D, and calcium values in terms of the initial and end of follow-up levels. No increase in the risk of premalignant gastric lesions was observed in the meta-analysis of RCTs in which PPI treatment (≥6 months) was given to Helicobacter pylori negative patients. The risk of hypomagnesemia with PPI use was increased in patients having GFR<60, using diuretics, and over 65 years of age. Quasi-experimental studies showed a reduced zinc absorption with PPI use. In the meta-analysis of OBS, long-term (>1 year) PPI use increased the risk of fundic polyps, but no risk was found in shorter use. The meta-analyses of RCTS showed no difference between PPI and surgery or placebo arms and between the arms of H2RA and placebo in terms of all side effects. No difference was found between the PPI and H2RA arms both in all and serious adverse effects. Cite this article as: Hatemi İ, Esatoğlu SN. What is the long term acid inhibitor treatment in gastroesophageal reflux disease? What are the potential problems related to long term acid inhibitor treatment in gastroesophageal reflux disease? How should these cases be followed? Turk J Gastroenterol 2017;28(Suppl 1); S57-S60 Full Text Turkish
Most read articles by the same author(s)
- Kadri Atay, Hayyam Eyvazov, Selma Bozcan, Tuğçe Eşkazan, Nurhan Demir, İbrahim Hatemi, Yusuf Erzin, Aykut Ferhat Çelik, The effect of concomitant ankylosing spondylitis on long-term outcome of patients with inflammatory bowel disease , Turkish Journal of Gastroenterology: Vol. 30 No. 7 (2019): Turkish Journal of Gastroenterology
- Kadri Atay, İbrahim Hatemi, Billur Canbakan, Emine Köroğlu, Emre Durcan, Berna Yurttaş, İlhami Gültepe, Sebati Özdemir, Murat Tuncer, Abdullah Sonsuz, Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B , Turkish Journal of Gastroenterology: Vol. 27 No. 3 (2016): Turkish Journal of Gastroenterology
- Hülya UZUNİSMAİL, İbrahim HATEMİ, Gülen DOĞUSOY, Onat AKIN, Dense eosinophilic infiltration of the mucosa preceding ulcerative colitis and mimicking eosinophilic colitis: Report of two cases , Turkish Journal of Gastroenterology: Vol. 17 No. 1 (2006): Turkish Journal of Gastroenterology
- Doğan SELÇUK, Kemal DEMİREL, Harun ÖZER, Bilgi BACA, İbrahim HATEMİ, İsmail MİHMANLI, Uğur KORMAN, Gündüz ÖĞÜT, Comparison of virtual colonoscopy with conventional colonoscopy in detection of colorectal polyps , Turkish Journal of Gastroenterology: Vol. 17 No. 4 (2006): Turkish Journal of Gastroenterology
- Ahmet Emre Eskazan, İbrahim Hatemi, Seniz Öngören Aydın, Muhlis Cem Ar, Teoman Soysal, Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy , Turkish Journal of Gastroenterology: Vol. 25 No. 1 (2014): Turkish Journal of Gastroenterology
Article Info
Published In
Journal
Turkish Journal of Gastroenterology
Volume / Issue
Volume 28 · Issue 1
Pages
S57-S60
History
Published Online
January 15, 2017
Copyright
Copyright (c) 2017 İbrahim Hatemi, Sinem Nihal Esatoğlu
Affiliations
İbrahim Hatemi
Departments of Gastroenterology, İstanbul University Cerrahpaşa Medical Faculty, İstanbul
Sinem Nihal Esatoğlu
Division of Rheumatology, Department of Internal Medicine, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
Cite this Article
Hatemi, İbrahim, & Esatoğlu, S. N. (2017). What is the long term acid inhibitor treatment in gastroesophageal reflux disease? What are the potential problems related to long term acid inhibitor treatment in gastroesophageal reflux disease? How should these cases be followed?. Turkish Journal of Gastroenterology, 28(1), S57-S60. https://doi.org/10.5152/tjg.2017.15
Outlines